Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20261803 | 0.89 | TP53 (0.41) | TSHRCYP2C19 | |
| SCHEMBL9439461 | 0.87 | — | — | |
| SCHEMBL20261806 | 0.85 | LMNA (0.35) | CYP2C19ALDH1A1 | |
| Phosphoric Acid SCHEMBL30132712 | 0.85 | ALDH1A1 (0.43) | ALDH1A1 | |
| Triclofos SCHEMBL125854 | 0.83 | FBP1 (0.38) | KDM4ECYP2C19KMT2A | |
| Triclofos SCHEMBL122124 | 0.81 | FBP1 (0.37) | KDM4ECYP2C19KMT2A | |
| SCHEMBL4995915 | 0.81 | KDM4E (0.31) | KDM4ECYP2C19KMT2A | |
| SCHEMBL27735699 | 0.80 | — | — | |
| SCHEMBL20543194 | 0.79 | — | — | |
| Triclofos SCHEMBL8970300 | 0.77 | KDM4E (0.44) | KDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106146548-B | Preparation and application of aryloxy phosphate monosodium salt | 中山大学 | 2020-12-29 | — | — | CN | disclosed |
| CN-111777638-A | Quinoline compound, preparation method, pharmaceutical composition and application thereof | 瀚海新拓(杭州)生物医药有限公司 | 2020-10-16 | — | — | CN | disclosed |
| US-7655646-B2 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | THALLION PHARMACEUTICALS, INC. (CA) | 2010-02-02 | — | — | US | disclosed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080161291-A1 | DIBENZODIAZEPINONE ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | THALLION PHARMACEUTICALS INC. | 2008-07-03 | — | — | US | disclosed |
| EP-1869027-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | Conforma Therapeutics Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7304054-B2 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | THALLION PHARMACEUTICALS INC. (CA) | 2007-12-04 | — | — | US | disclosed |
| US-7235666-B2 | Sulfonation of 3-(hydroxymethyl)-5,5-diphenylimidazolidine-2,4-dione followed by phosphating in the presence of trisubstituted aliphatic amine base and a polar aprotic solvent; anticonvulsants, antiepileptic and antiarrhythmia agent | CILAG LTD. (CH) | 2007-06-26 | — | — | US | disclosed |
| US-7153901-B2 | Low viscosity flame retardants are the reaction product of a mixed ester of tetrabromophthalic acid with diethylene glycol and propylene glycol with an acid anhydride, organic phosphate, or organic chlorophosphate; minimizing visible scorching of the flexible polyurethane foam during its production | ALBEMARLE CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| WO-2006105372-A2 | ALKYNYL PYRROLOPYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060079512-A1 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | ECOPIA BIOSCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060079509-A1 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | ECOPIA BIOSCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20050272706-A1 | Process for the preparation of sodium fosphenytoin | CILAG, LTD. | 2005-12-08 | — | — | US | disclosed |
| WO-2005052018-A2 | FLAME RETARDANT, ADDITIVE COMPOSITIONS, AND FLAME RETARDANT POLYURETHANES | ALBEMARLE CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| US-20050113495-A1 | Flame retardant, additive compositions, and flame retardant polyurethanes | ALBEMARLE CORPORATION | 2005-05-26 | — | — | US | disclosed |
| US-4880922-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1989-11-14 | — | — | US | disclosed |
| US-4746736-A | THIENAMYCINS, BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1988-05-24 | — | — | US | disclosed |
| US-4732977-A | BACTERICIDES | BRISTOL MYERS COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| US-4665169-A | THIENAMYCIN BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1987-05-12 | — | — | US | disclosed |
| US-4644061-A | Carbapenem antibiotics | BRISTOL-MYERS COMPANY (US) | 1987-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272706-A1 | Process for the preparation of sodium fosphenytoin | FOS, DUSP5, DCPS | TSHR 3700/4885KDM4E 390/4885CYP2C19 148/4885 |
| US-20060079509-A1 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | UGT2B17, CYP1B1, CYP2C19 | TSHR 1601/4885KDM4E 2408/4885CYP2C19 3/4885 |
| US-20060079512-A1 | Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals | UGT2B17, CYP1B1, CYP2C19 | TSHR 1601/4885KDM4E 2408/4885CYP2C19 3/4885 |
| US-20080161291-A1 | DIBENZODIAZEPINONE ANALOGUES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS | UGT2B17, CYP1B1, CYP2C19 | TSHR 1601/4885KDM4E 2408/4885CYP2C19 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.